☕️ Since I’ve been seeing a lot of debate in the field lately, I’ve decided to provide a set of Guidelines for the management of a good 🇮🇹 coffee
1️⃣st - get a Moka. Better if an old one: just as wine, it gets better with the passing of time. Wash the Moka. Open the Moka.
[1/5]
2️⃣nd - Pour some water in the Moka. The right amount.
If you put too much, you get colored water 💧 . If you put to little, you’ve got no coffee to offer to other people. 🤷🏻♂️
Best is to reach just under the tiny valve. No rocket science.
[2/5]
3️⃣rd - I call this step “The Everest”.
In short, put on the filter as much coffee as it fits. Then you add some more. And then some more.
❌DO NOT PRESS.
Coffee doesn’t like to get pressed. Nobody does.
Just make it gently fall from above, & make the mountain appear ⛰
[3/5]
4️⃣th - We’re almost done - but let’s keep attention high, we’re playing with fire now 🔥
Coffee needs time. If you rush it, you burn it.
Coffee needs a small, gentle, respectful fire - and some patience. So - keep the flame low, and relax for a few minutes.
[4/5]
5️⃣th - And the magic is done!
A hot, dark, fragrant, tasty coffee is ready to give you the energy to write your next @NEJM - or to follow an intense afternoon of #ASCO21 presentations!
References for this Guideline will be available in the full publication.
No COI.
[5/5]
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Reading good review articles can shape ideas, help connecting the dots and understanding what’s coming ahead in science.
Here’s 10 review articles that helped me shape my views on breast oncology and drug development:
1. The basics, first. What is breast cancer? How do we classify it, how do we treat it? In this article, Ada Waks et al. provide a comprehensive view of the clinical management of breast cancer, recapitulating decades of advancements in the field. jamanetwork.com/journals/jama/…
2. Now, a deeper dive into the subtypes. Despite being intensively studied, ER+ breast cancer remains elusive in many aspects. In this article, @DrHBurstein reviews the biology and paradigms behind the treatment of the most common subtype of breast cancer. nejm.org/doi/full/10.10…
Proud to contribute to the remarkable scientific journey of #APT, whose 10-year analysis is now published on @TheLancetOncol. Adjuvant TH confirmed outstanding long-term outcomes for patients with small HER2+ breast cancer. Aim for the next decade: biomarker-informed treatments!
Great idea: time for Elacestrant thread Tuesday! 🧵
But first a reminder: access to paywalled papers from @Annals_Oncology, @ESMO_Open & multiple other affiliated journals is free for @myESMO members, and I could not recommend more to become a member! esmo.org/membership 1/
Endocrine treatment is among the most effective treatment strategies we have for breast cancer. 50 years ago, the approval of the SERD tamoxifen really revolutionized the field, & we still use the drug today.
Yet, no novel ET had been approved for the last 20 years. Until now 2/
Multiple oral SERDs (selective estrogen receptor degraders) are being developed for patients with HR+ MBC. The first to achieve positive phase 3 results was elacestrant, tested in the #EMERALD trial vs. SoC ET (fulvestrant or AI). Primary endpoint -> PFS overall & in ESR1-mut